Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to 0.55%.

  • Zentalis Pharmaceuticals' Return on Capital Employed fell 400.0% to 0.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.55%, marking a year-over-year decrease of 400.0%. This contributed to the annual value of 0.44% for FY2024, which is 1900.0% up from last year.
  • Zentalis Pharmaceuticals' Return on Capital Employed amounted to 0.55% in Q3 2025, which was down 400.0% from 0.56% recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' Return on Capital Employed ranged from a high of 0.48% in Q4 2022 and a low of 0.6% during Q4 2023
  • In the last 4 years, Zentalis Pharmaceuticals' Return on Capital Employed had a median value of 0.52% in 2024 and averaged 0.53%.
  • In the last 5 years, Zentalis Pharmaceuticals' Return on Capital Employed crashed by -1200bps in 2023 and then surged by 1100bps in 2024.
  • Over the past 4 years, Zentalis Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.48% in 2022, then dropped by -26bps to 0.6% in 2023, then grew by 18bps to 0.49% in 2024, then decreased by -11bps to 0.55% in 2025.
  • Its Return on Capital Employed stands at 0.55% for Q3 2025, versus 0.56% for Q2 2025 and 0.59% for Q1 2025.